Subharmonic-Aided Pressure Estimation (SHAPE) of Pancreatic Adenocarcinomas Undergoing Chemotherapy with Sonoporation – Preliminary Results
Monday, April 8, 2024
11:10am – 11:17am
Location: 410
Authors: Priscilla Machado, Thomas Jefferson University Hailee Mayer, Thomas Jefferson University Trang Vu, Thomas Jefferson University Hospital John Eisenbrey, Thomas Jefferson University James Posey III, Thomas Jefferson university Spiros Kotopoulis, University of Bergen Babar Bashir, Sidney Kimmel Cancer Center at Thomas Jefferson University Patrick Mille, TJUH Atrayee Basu Mallick, TJUH Daniel Lin, Thomas Jefferson University Hospital Ingrid Nordaas, Haukeland University Hospital Audun Trelsgård, Haukeland University Hospital Georg Dimcevski, Haukeland University Hospital, Bergen, Norway Odd Helge Gilja, Haukeland University Hospital Kirk Wallace, GE HealthCare Technology and Innovation Center Flemming Wallace, Thomas Jefferson University
Sonoporation is a novel method that can enhance the therapeutic efficacy of co-administered chemotherapy by performing localized contrast-enhanced ultrasound (CEUS) imaging at the time of optimal chemotherapy concentration in the blood. TAn ongoing Phase II clinical trial aims to improve standard of care (SoC) chemotherapy treatment of pancreatic adenocarcinoma (PDAC) by adding sonoporation. As part of this study, a non-invasive ultrasound technique, subharmonic-aided pressure estimation (SHAPE), was used to estimate intra-tumoral pressure measurements. The mean dB values showed that for responders there was an decrease in SHAPE intra-tumoral measurements (indicating a pressure increase) from the first to the last cycle, however no statistical difference was observed between the first and last cycle translating in significant statistical difference between the third and the last cycle (p = 0.28). The mean dB values showed that for non-responders there was significant increase in SHAPE intra-tumoral measurements (indicating a pressure decrease) from the first to the last cycle (p = 0.0002). Most importantly, results showed that between responders and non-responders there was significant statistical difference for the first cycle (p = 0.01) and third cycle (p = 0.002). These preliminary results suggest that SHAPE intra-tumoral pressure measurements may be used to indicate chemotherapy response.